'NfL' Biomarker Associated With Disability Progression in Large Swedish Study of People With MS
May 21, 2020
May 21, 2020
NEW YORK, May 21 -- The National Multiple Sclerosis Society issued the following news:
Higher blood levels of a molecule called Neurofilament light chain (NfL) were associated with progression of disability in blood samples from 4,385 people with MS. Although further study is needed before this blood test can be used routinely to predict disease course and guide the care of individuals with MS, these findings add to growing evidence that NfL has potential as a predictive biomarker o . . .
Higher blood levels of a molecule called Neurofilament light chain (NfL) were associated with progression of disability in blood samples from 4,385 people with MS. Although further study is needed before this blood test can be used routinely to predict disease course and guide the care of individuals with MS, these findings add to growing evidence that NfL has potential as a predictive biomarker o . . .